PD-L1
信号转导
小分子
免疫系统
免疫疗法
单克隆抗体
癌症研究
癌症免疫疗法
细胞信号
化学
抗体
生物
细胞生物学
磷酸化
免疫学
生物化学
作者
Qian Wu,Li Jun Jiang,Sicheng Li,Qiaojun He,Bo Yang,Ji Cao
标识
DOI:10.1038/s41401-020-0366-x
摘要
Tumor cells form immune escape and subsequently obtain unlimited proliferation ability due to the abnormal immune surveillance mediated by immune checkpoints. Among this class of immune checkpoints, PD-1/PD-L1 was recognized as an anticancer drug target for many years, and so far, several monoclonal antibodies have achieved encouraging outcome in cancer treatment by targeting the PD-1/PD-L1 signaling pathway. Due to the inherent limitations of antibodies, the development of small molecule inhibitors based on PD-1/PD-L1 signaling pathway is gradually reviving in decades. In this review, we summarized a number of small molecule inhibitors based on three different therapeutic approaches interfering PD-1/PD-L1 signaling pathway: (1) blocking direct interaction between PD-1 and PD-L1; (2) inhibiting transcription and translation of PD-L1; and (3) promoting degradation of PD-L1 protein. The development of these small molecule inhibitors opens a new avenue for tumor immunotherapy based on PD-1/PD-L1 signaling pathway.
科研通智能强力驱动
Strongly Powered by AbleSci AI